Knee Embolization (GAE): An Emerging Treatment for Knee Arthritis Pain

---

If you have been dealing with knee osteoarthritis pain that has not improved with physical therapy, injections, or medications, you may have come across a newer option called knee embolization — formally known as geniculate artery embolization (GAE).

This procedure takes a completely different approach than traditional treatments. Instead of adding lubrication to the joint (like gel injections) or blocking pain signals (like nerve blocks), GAE targets the abnormal blood vessels that fuel inflammation inside your arthritic knee.

The research is still early, but the results so far are promising. Here is what you need to know.

---

What Is Knee Embolization (GAE)?

The Science Behind It

When osteoarthritis develops in your knee, the joint lining (called the synovium) becomes inflamed. This inflammation triggers the growth of abnormal new blood vessels — a process doctors call neovascularization. These abnormal vessels do two things that make your pain worse:

1. They deliver more inflammatory chemicals to the joint, keeping the cycle of inflammation going
2. They bring in new nerve fibers (neoinnervation) that make the area more sensitive to pain

GAE works by selectively blocking these abnormal blood vessels. An interventional radiologist threads a tiny catheter through an artery — usually in the upper thigh — and guides it to the small arteries around your knee (called genicular arteries). Once there, they inject microscopic beads (called microspheres) that plug the abnormal vessels feeding the inflamed tissue.

By cutting off blood supply to the inflamed synovium, GAE reduces both the inflammation and the nerve sensitivity that cause your pain.

What GAE Does Not Do

It is important to understand what this procedure is not:

• It does not regrow cartilage or reverse arthritis damage
• It does not replace the joint like knee replacement surgery
• It does not block nerve signals like radiofrequency ablation
• It is not a cure for osteoarthritis

GAE is a pain management procedure that targets the inflammatory component of knee OA. Your arthritis is still there, but the painful inflammation may be significantly reduced.

---

How the Procedure Works

GAE is performed as an outpatient procedure — you go home the same day. Here is what to expect step by step.

Before the Procedure

• Your doctor reviews imaging (X-rays, possibly MRI) to confirm osteoarthritis and assess the level of joint inflammation
• Radiopaque markers may be placed on your skin at the points where you feel the most pain, helping guide the radiologist during the procedure
• You receive local anesthesia and light sedation (you are awake but relaxed)

During the Procedure (60-90 Minutes)

1. Arterial access: A small puncture is made in the upper thigh (femoral artery) or sometimes the wrist (radial artery). No surgical incision is needed.

2. Catheter navigation: Using real-time X-ray imaging (fluoroscopy), the radiologist guides a thin catheter and even thinner microcatheter into the genicular arteries around your knee.

3. Identifying abnormal vessels: Contrast dye is injected to reveal which arteries are feeding the inflamed synovial tissue. These show up as areas of abnormal “blush” on the imaging.

4. Embolization: Tiny microspheres (typically 100-300 micrometers, smaller than a grain of sand) are carefully injected to block the abnormal vessels. The radiologist stops when the inflammatory blush disappears while keeping the main artery open.

5. Completion: The catheter is removed, and a small bandage is placed over the puncture site.

After the Procedure

• You rest in recovery for a few hours while the sedation wears off
• Most patients go home 4-6 hours after the procedure
• You can walk immediately but should avoid strenuous activity for 1-2 weeks
• Mild knee soreness is normal for 3-5 days

---

Clinical Evidence: What Research Shows

Key Studies and Results

Several clinical trials have evaluated GAE for knee osteoarthritis pain. Here are the most important findings:

What the Numbers Mean

Across studies, the general pattern shows:

• 50-70% of patients experience at least 50% pain reduction at 12-24 months
• 78% meet the “minimally clinically important difference” for pain improvement — meaning the improvement is large enough to notice in daily life
• 92% show meaningful functional improvement on standardized questionnaires
• Results are best in patients with moderate disease (Kellgren-Lawrence grades 2-3)
• Only about 5% of patients go on to need knee replacement during follow-up periods

Ongoing Trials to Watch

Several major trials will provide more data in the coming years:

• MOTION Trial: An international RCT comparing GAE to cortisone injections across the US, UK, Australia, Brazil, and Canada
• GENESIS II: A UK-based RCT comparing GAE to sham procedure
• GRAVITY Trial: Comparing GAE to conservative management (results expected 2027)
• RESORB Trial: The first US FDA pivotal trial testing a new resorbable microsphere (Nexsphere-F), which dissolves within hours rather than blocking vessels permanently

---

How GAE Compares to Other Treatments

Where GAE Fits In

GAE fills a specific gap in the treatment ladder. It may be a good option when:

• Cortisone injections provide only short-term relief or have stopped working
• HA injections are not providing enough benefit
• You are not ready for knee replacement or want to delay it
• You want longer-lasting relief than what injections typically provide

It is important to note that GAE is not meant to replace these proven treatments. For many patients, starting with conservative options — physical therapy, weight management, medications, and injections — remains the right first step.

---

Cost and Insurance Coverage

Current Cost Landscape

GAE costs vary significantly depending on where you have the procedure:

• Estimated total cost: $3,000-$15,000 (facility fees, radiologist fees, imaging, supplies)
• Most common range: $5,000-$10,000

Insurance Coverage (As of Early 2026)

Coverage for GAE is currently limited and variable:

Medicare (Traditional)

• Generally covers 80% of the procedure cost
• Patient responsibility: approximately $1,500-$2,500 after deductibles
• Medicare + Medigap supplement may result in minimal out-of-pocket costs

Medicare Advantage

• Coverage varies by plan
• Some plans have fixed copays (around $75)
• Prior authorization typically required

Commercial Insurance (Aetna, BCBS, Cigna, Humana, UnitedHealthcare)

• Most currently classify GAE as “investigational” or “experimental”
• Coverage denials are common
• Medical exceptions may be granted when patients are ineligible for surgery, have failed other treatments, or have medical conditions making surgery too risky

Will Coverage Improve?

There are positive signs. One new resorbable microsphere (Nexsphere-F) has received FDA Breakthrough Device Designation and CMS IDE Category B approval, which provides Medicare coverage for patients enrolled in its clinical trial. As more trial data is published and FDA-approved devices reach the market, broader insurance coverage is likely to follow — though this process may take several years.

---

Who Is a Good Candidate?

Potentially Good Candidates

GAE may be worth discussing with your doctor if you:

• Have moderate knee osteoarthritis (Kellgren-Lawrence grades 2-3) confirmed on X-ray
• Experience persistent knee pain despite at least 3-6 months of conservative treatment
• Have tried physical therapy, medications, and/or injections without adequate relief
• Are not ready for knee replacement or want to delay surgery
• Are not a good surgical candidate due to other health conditions, obesity, or blood thinner use
• Have localized tenderness around the knee (suggesting active synovial inflammation)

Less Ideal Candidates

GAE may not be the best option if you:

• Have severe “bone-on-bone” arthritis (KL Grade 4) — results tend to be less durable
• Are a good candidate for knee replacement and ready for definitive treatment
• Have significant peripheral artery disease (the genicular arteries serve as important blood supply pathways)
• Have an active infection or malignancy near the knee
• Expect a complete cure for your arthritis

Age Range

Most clinical trials have enrolled patients aged 40-80. There is limited data on patients under 40 or over 80.

---

Risks and Limitations

Known Risks

Based on clinical trial data, GAE has a favorable safety profile, but risks include:

• Skin discoloration near the knee (most common; occurs in about 12% of patients, typically resolves within days)
• Minor bruising or soreness at the catheter insertion site
• Temporary numbness or tingling in the leg (rare, usually resolves within 2 weeks)
• Groin hematoma at the access site (rare)
• Deep vein thrombosis (very rare; one case reported in the GENESIS trial, attributed to patient immobilization)

What Has NOT Been Seen

Importantly, across published trials:

• No osteonecrosis (bone death) has been found on follow-up MRI scans
• No cartilage damage has been attributed to the procedure
• No serious systemic complications (infection, organ damage) have been reported
• GAE does not prevent future knee replacement if you eventually need one

Key Limitations

• Long-term data is limited — most studies have 1-2 year follow-up, with some extending to 3-4 years
• Not all patients respond — about 20-30% may not achieve meaningful pain relief
• No standardized protocol yet — embolic materials, particle sizes, and techniques vary between centers
• Results may fade over time — some patients may need repeat treatment
• Study sizes are still small — the largest meta-analysis includes 270 patients across 9 studies

---

Where to Find GAE Providers

GAE is performed by interventional radiologists — doctors who specialize in image-guided, catheter-based procedures. Finding an experienced provider is important.

Where to Look

• Academic medical centers with interventional radiology departments (many leading hospitals now offer GAE)
• Specialized vascular and interventional radiology practices in major metro areas
• Clinical trial sites — enrolling in a trial may provide access to GAE with reduced or no cost

What to Ask a Potential Provider

1. How many GAE procedures have you performed? (Look for providers with meaningful experience)
2. What embolic material do you use? (Microspheres, imipenem/cilastatin, or resorbable beads each have different profiles)
3. What outcomes have your patients experienced? (Ask for their own results data)
4. Do you track your results systematically?
5. What is the total cost, and will your office help with insurance?

---

Frequently Asked Questions

Is GAE FDA-approved?

No. As of early 2026, GAE is not specifically FDA-approved for knee osteoarthritis. The embolic materials used (microspheres) are FDA-cleared for other conditions (like uterine fibroids), but their use in knee OA is considered off-label. Multiple FDA-tracked clinical trials are underway, including the RESORB pivotal trial, which could lead to the first FDA-approved device specifically for this procedure.

How long does pain relief last after GAE?

Clinical studies show meaningful pain relief lasting 12-24 months in most responders. Some patients report benefits extending 3-4 years after a single procedure. However, since osteoarthritis is a progressive condition, pain may eventually return. The procedure can typically be repeated if needed.

Can I have GAE on both knees?

Yes, but typically one knee is treated at a time. Your doctor may recommend waiting several weeks between procedures. Some clinical protocols treat both knees in a single session, but this is less common.

Is GAE painful?

Most patients report minimal discomfort during the procedure thanks to local anesthesia and sedation. You may feel pressure or warmth in your knee during the embolization. Post-procedure soreness is typically mild and manageable with over-the-counter pain medication for 3-5 days.

How does GAE compare to PRP injections?

Both are relatively newer approaches for knee OA. PRP injections use concentrated platelets from your own blood to promote healing. GAE targets the inflammatory blood vessels directly. PRP effects typically last 6-12 months, while GAE may provide 12-24 months of relief. They target different aspects of osteoarthritis and could potentially complement each other, though no studies have evaluated combining them.

What if GAE does not work for me?

If GAE does not provide adequate relief, all other treatment options remain available. You can still pursue cortisone injections, hyaluronic acid injections, physical therapy, or knee replacement surgery. GAE does not limit your future options.

---

---

Related Resources

• Knee Osteoarthritis: Complete Guide — Understanding your condition
• Non-Surgical Knee Arthritis Treatments — All your options before surgery
• Regenerative Medicine for Joint Pain — PRP, stem cells, and emerging therapies
• Three Types of Knee Injections Compared — Cortisone, HA, and PRP
• Hyaluronic Acid Injections — How gel shots work

---

References

1. Bagla S, Piechowiak R, Hartman T, et al. Genicular artery embolization for the treatment of knee pain secondary to osteoarthritis. J Vasc Interv Radiol. 2022;33(1):2-9.
2. Little M, et al. GENESIS trial: Genicular artery embolization for knee osteoarthritis — 24-month outcomes. J Vasc Interv Radiol. 2024.
3. Taslakian B, et al. Meta-analysis of genicular artery embolization for knee osteoarthritis: safety and efficacy across 270 patients and 339 knees. Osteoarthritis Cartilage Open. 2025.
4. Landers S, et al. Genicular artery embolization for early-to-moderate knee osteoarthritis: randomized controlled trial. Radiology. 2023;307(2).
5. MOTION trial. Comparison of genicular artery embolization vs intra-articular corticosteroid injection (NCT05818150). ClinicalTrials.gov.
6. NEXTBIOMEDICAL. First patient enrolled in US FDA pivotal trial of Nexsphere-F for knee osteoarthritis pain (RESORB trial). Press release, October 2025.
7. Ashraf A, et al. Systematic review of safety and efficacy of GAE for managing knee osteoarthritis. 2025.
8. Okuno Y, et al. Transcatheter arterial embolization as a treatment for medial knee pain in patients with mild to moderate osteoarthritis. Cardiovasc Intervent Radiol. 2015;38(2):336-343.

---

Last reviewed: March 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Geniculate artery embolization is an emerging procedure that is not FDA-approved for knee osteoarthritis. Evidence is promising but limited to relatively small clinical trials with short-to-medium-term follow-up. Discuss all treatment options with your healthcare provider. Individual results vary, and not all patients will experience the outcomes described in clinical studies.